Symbole | YTM % | Volume | Prix % | Coupon % | Date d'échéance | Montant en suspens | Valeur nominale | Montant min de la dénomination | Émetteur |
---|---|---|---|---|---|---|---|---|---|
UUSU3149FAB5FRES.MED.III 20/31 REGS | 6,61% | 0 | 81,29% | 2,38% | 2031-02-16 | 1 B USD | 1 000,00 USD | 150 000,00 USD | Fresenius Medical Care US Finance III, Inc. |
FFMS5184425Fresenius Medical Care US Finance III, Inc. 3.0% 01-DEC-2031 | 6,33% | 50 K | 83,80% | 3,00% | 2031-12-01 | 650 M USD | 1 000,00 USD | 150 000,00 USD | Fresenius Medical Care US Finance III, Inc. |
UUS35805BAA61FreMedCarUSFin3 3,75% 15/06/2029 Rule 144A | 5,55% | 0 | 93,45% | 3,75% | 2029-06-15 | 500,15 M USD | 2 000,00 USD | 150 000,00 USD | Fresenius Medical Care US Finance III, Inc. |
FFMS5184423Fresenius Medical Care US Finance III, Inc. 1.875% 01-DEC-2026 | 5,38% | 261 K | 93,61% | 1,88% | 2026-12-01 | 850 M USD | 1 000,00 USD | 150 000,00 USD | Fresenius Medical Care US Finance III, Inc. |
UUSU3149FAA76FreMedCarUSFin3 3,75% 15/06/2029 Reg S | 5,17% | 0 | 94,77% | 3,75% | 2029-06-15 | 500,15 M USD | 2 000,00 USD | 150 000,00 USD | Fresenius Medical Care US Finance III, Inc. |
FMEEFRESE.MED.CARE MTN 20/30 | 3,50% | 0 | 90,74% | 1,50% | 2030-05-29 | 750 M EUR | 1 000,00 EUR | 1 000,00 EUR | Fresenius Medical Care AG |
XS2084488209FreseniusMedCar 1,25% 29/11/2029 | 3,17% | 0 | 91,67% | 1,25% | 2029-11-29 | 500 M EUR | 1 000,00 EUR | 1 000,00 EUR | Fresenius Medical Care AG |
XS253044462FRESE.MED.CARE MTN 22/27 | 2,91% | 0 | 102,52% | 3,88% | 2027-09-20 | 750 M EUR | 1 000,00 EUR | 1 000,00 EUR | Fresenius Medical Care AG |
XS208449770FRESE.MED.CARE MTN 19/26 | 2,82% | 0 | 95,80% | 0,63% | 2026-11-30 | 600 M EUR | 1 000,00 EUR | 1 000,00 EUR | Fresenius Medical Care AG |
FMEDFRESE.MED.CARE MTN 20/26 | 2,77% | 0 | 97,43% | 1,00% | 2026-05-29 | 500 M EUR | 1 000,00 EUR | 1 000,00 EUR | Fresenius Medical Care AG |
XS185453294FRESE.MED.CARE MTN 18/25 | 2,74% | 0 | 99,23% | 1,50% | 2025-07-11 | 500 M EUR | 1 000,00 EUR | 1 000,00 EUR | Fresenius Medical Care AG |